Published 3 months ago

Anocca Appoints Martin Welschof to Board of Directors

Summary by Ground News

Martin Welschof is currently CEO of BioInvent International AB, a listed clinical-stage cancer immunotherapy company. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld. Anocca recently gained a GMP license for the largest cell-therapy manufacturing facility in the Nordics.

0 Articles

All

Left

Center

Right

Benzinga

Anocca Appoints Martin Welschof to Board of Directors

SÖDERTÄLJE, Sweden, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. Martin Welschof is currently CEO of BioInvent International AB, a listed clinical-stage cancer immunotherapy company. Martin holds a PhD in the field of recombinant antibody technology from the University of Bielefeld. "We're delighted to welcome Martin to our boar…

3 months ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.